Bevacizumab
HS-20089, a B7-H4-targeted antibody-drug conjugate developed by Hansoh Pharma, has demonstrated promising efficacy in heavily pretreated patients with platinum-resistant ovarian cancer (PROC). The phase 2 study found a confirmed objective response rate (ORR) of 48.5%, a median duration of response (DoR) of 6.8 months, a median progression-free survival
Aflibercept
DelveInsight's "Diabetic Macular Edema Pipeline Insight 2025" report provides comprehensive insights about 45+ companies and 50+ pipeline drugs in Diabetic Macular Edema pipeline landscape. The report covers the Diabetic Macular Edema pipeline drug profiles, including clinical and nonclinical stage products, and provides therapeutic assessment by product
Aflibercept
A new systematic review and meta-analysis published in the Graefe's Archive for Clinical and Experimental Ophthalmology has found that switching to faricimab after prior anti-vascular endothelial growth factor (VEGF) therapy can significantly improve symptoms of diabetic macular edema (DME). The study, conducted by researchers at Tabriz University of
Bevacizumab
Diabetic macular edema (DME), a leading cause of blindness, requires costly treatment with anti-vascular endothelial growth factor (VEGF) agents. However, a recent retrospective cohort study has estimated the long-term patient-centered economic burden of DME, revealing significant costs and utilization compared to those with diabetes mellitus (DM) without DME. The study
Aflibercept
Researchers at the University of Texas Medical Branch in Galveston, Texas, have published a new study on the treatment of macular edema, a common cause of vision loss in people with diabetes. The study, which was presented in the Middle East African Journal of Ophthalmology, found that a treatment protocol
Bevacizumab
Research conducted by Maharaja Agrasen Medical College has made significant strides in finding an effective and affordable treatment for diabetic macular edema (DME). The study, published in the Indian Journal of Pharmacology, investigated the efficacy and safety of biosimilars of bevacizumab, an off-label anti-vascular endothelial growth factor (VEGF) therapy, in
